Skip to content

The Evaluation of NETs, Caspase-1 and Cytokines in ARDS Patients

IRF-1 Regulate Alveolar Macrophage Pyroptosis in Acute Lung Injury and of Which Will be Possible Mechanism

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03227107
Enrollment
100
Registered
2017-07-24
Start date
2016-01-01
Completion date
2020-12-30
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS

Brief summary

1. enrollment criteria and clinical data collection: follow the principles of medical ethics, the development of inclusion and exclusion criteria, select 90 cases of ARDS patients, in the active treatment at the same time, according to the Berlin standard severity of the disease divided into mild group, moderate Group and severe group, according to the prognosis during hospitalization is divided into survival group and death group. BALF specimens were collected on the day of admission to detect the levels of NETs and alveolar macrophages. The acute and chronic health status scoring system Ⅱ (APACHEⅡ) and Murray acute lung injury score, blood routine, creatinine, urea nitrogen, fasting blood glucose, Item, mean arterial pressure, arterial blood gas analysis, oxygenation index; record the patient's mechanical ventilation time and other data; 2. Pearson linear correlation analysis of BALF in the content of NETs, alveolar macrophage coke death level was a positive correlation between the Spearman rank correlation analysis BALF in the NETs content and alveolar macrophage coke death level, APACHE Ⅱ, Murray score, creatinine, Urea nitrogen, fasting blood glucose and other indicators and ARDS severity was positively correlated; 3. To analyze the prognostic factors of different prognostic factors, to evaluate the content of NETs in BALF, the level of alveolar macrophage coke, APACHEⅡ and Murray scores were analyzed by receiver operator characteristic curve (ROC curve) Short - term survival outcome prognostic value.

Interventions

None listed

Sponsors

National Natural Science Foundation of China
CollaboratorOTHER_GOV
Xiangya Hospital of Central South University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* ARDS patients diagnosis within 3 days * Over 18 years old but no more than 75 years old

Exclusion criteria

* Severe thoracic open trauma * Pulmonary embolism * Severe cardiovascular and cerebrovascular disease * Endocrine system diseases * Coagulation dysfunction * Liver and kidney failure * Malignant tumors * Cardiogenic pulmonary edema

Design outcomes

Primary

MeasureTime frameDescription
neutrophil extracellular traps, caspase-1,cytokines measurement4 yearsAssessments with neutrophil extracellular traps be presented in ng/ml; Assessments with caspase-1 and cytokines be presented in pg/ml

Countries

China

Contacts

Primary ContactLi Haitao, Doctor
168101013@csu.edu.cn(+86)18684916132
Backup ContactPan Pinhua, Doctor
pinhuapan668@126.com(+86)13574810968

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026